A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: July 13, 2022

Our understanding of the immune responses that follow SARS-CoV-2 infection and vaccination has progressed considerably since COVID-19 pandemic was first declared on 11 th March in 2020. Recovery from is associated with development protective responses, although over time these become less effective against new emerging variants. Consequently, reinfection variants not infrequent contributed to ongoing pandemic. vaccines have had a tremendous impact reducing particularly number deaths infection. However, waning vaccine induced immunity plus emergence necessitated use boosters maintain benefits deaths. Boosting also beneficial for individuals who recovered developed natural immunity, enhancing This review summarizes our vaccination, risks very important role boosting plays both vaccinated previously infected individuals.

Language: Английский

---

Neutralizing SARS-CoV-2 Spike Antibodies against Omicron in Paired Samples after Two or Three Doses of mRNA Vaccine

Microbiology Spectrum, Journal Year: 2022, Volume and Issue: 10(5)

Published: Oct. 3, 2022

SARS-CoV-2 antibody levels wane following two-doses of mRNA vaccination. An booster dose provides increased protection against hospitalization and death. We demonstrated that a significant increase in the neutralization Beta, Delta Omicron variants addition to an vaccine strain. The total spike IgG measurements, obtained by using commercial kits target protein from strain, may not reflect serum concern. IMPORTANCE This study found little no neutralizing capability 2-dose series omicron variant, capacity any variant strain tested was lost 8-months post series. However, eliminated immune escape observed Even more, titers were significantly higher for all post-boost, compared post-two-dose Our data are unique, paired samples eliminate potential confounders impact response. Notably, as seen after primary two-dose series, did correlate perfectly with activity, suggesting simply testing measure be long-term solution. Therefore, it is important reassess utility testing, current strain-based reliably detect reactive antibodies or other

Language: Английский

---

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up

Clinical Microbiology and Infection, Journal Year: 2023, Volume and Issue: 29(7), P. 918 - 923

Published: March 13, 2023

Language: Английский

---

High Concentration of Anti-SARS-CoV-2 Antibodies 2 Years after COVID-19 Vaccination Stems Not Only from Boosters but Also from Widespread, Often Unrecognized, Contact with the Virus

Vaccines, Journal Year: 2024, Volume and Issue: 12(5), P. 471 - 471

Published: April 28, 2024

This study follows 99 subjects vaccinated with Pfizer/BioNTech COVID-19 vaccines over two years, particular focus on the last year of observation (between days 360 and 720). The response to vaccination was assessed Diasorin's SARS-CoV-2 TrimericSpike IgG. Screening for infection performed Abbott's Nucleocapsid IgG immunoassay. Data from questionnaires were also analyzed. Two years after first vaccine dose administration, 100% positive anti-spike median antibody level still high (3600 BAU/mL), dropping insignificantly year. Simultaneously, a substantial increase in seropositivity anti-nucleocapsid noted, reaching 33%. There no statistically significant agreement between anti-N reported COVID-19. Higher concentrations lower incidence seen older vaccinees. It noted that only boosted 720 showed an concentrations. higher (median 7440 BAU/mL) day participants not infected following Vaccination, including booster administrations, natural, even unrecognized, contact entwined primary vaccination, leading

Language: Английский

---

Comparison of total and neutralizing SARS-CoV-2 spike antibodies against omicron and other variants in paired samples after two or three doses of mRNA vaccine

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2022, Volume and Issue: unknown

Published: Jan. 28, 2022

Recognizing that anti-SARS-CoV-2 antibody levels wane over time following the 2-dose SARS-CoV-2 mRNA series, FDA approved a booster dose for people greater than 12 years old. Limited data exist on whether of vaccine results in protection primary series. We examined total and neutralizing antibodies to spike protein SARS-CoV-2, against Washington-1 (WA-1) variants concern (VOC) including Beta, Delta Omicron longitudinal cohort. Healthcare workers (HWs) were included analysis if serum was collected 1) within 14-44 days post-dose2 an (Timepoint 1, TP1), or 2) at least 8 months 2, TP2), 3) 3, TP3). HWs with prior covid-positive PCR excluded. found there is little no capability series omicron variant, capacity any variant strain tested has been lost by 8-months post two-dose vaccination However, eliminates immune escape observed Neutralizing titers significantly higher all post-boost compared The nature our cohort facilitated paired samples pre boost, showing 15-fold increase neutralization these samples. An provides quantity quality regimen critical provide variant.

Language: Английский

---